American Century Companies Inc. Lowers Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

American Century Companies Inc. reduced its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) by 52.4% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,038,610 shares of the company’s stock after selling 2,247,295 shares during the quarter. American Century Companies Inc. owned 0.53% of GoodRx worth $9,480,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Gagnon Securities LLC increased its holdings in shares of GoodRx by 9.9% during the 4th quarter. Gagnon Securities LLC now owns 69,867 shares of the company’s stock valued at $325,000 after purchasing an additional 6,266 shares in the last quarter. Swiss National Bank boosted its stake in shares of GoodRx by 4.1% during the 4th quarter. Swiss National Bank now owns 161,400 shares of the company’s stock worth $751,000 after acquiring an additional 6,400 shares in the last quarter. Fortem Financial Group LLC grew its position in shares of GoodRx by 7.2% during the 4th quarter. Fortem Financial Group LLC now owns 119,179 shares of the company’s stock valued at $554,000 after acquiring an additional 7,996 shares during the period. EP Wealth Advisors LLC purchased a new position in shares of GoodRx in the 3rd quarter valued at about $73,000. Finally, Versor Investments LP acquired a new position in GoodRx in the 4th quarter worth about $54,000. Hedge funds and other institutional investors own 63.77% of the company’s stock.

GoodRx Stock Performance

GoodRx stock opened at $4.57 on Thursday. GoodRx Holdings, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $9.26. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -152.33, a PEG ratio of 2.46 and a beta of 1.25. The stock has a fifty day moving average of $4.75 and a two-hundred day moving average of $5.23. The company has a debt-to-equity ratio of 0.70, a quick ratio of 5.48 and a current ratio of 5.48.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wells Fargo & Company reduced their target price on GoodRx from $9.00 to $8.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. KeyCorp decreased their price objective on shares of GoodRx from $7.00 to $6.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Citigroup cut their target price on shares of GoodRx from $7.00 to $6.25 and set a “buy” rating for the company in a research note on Friday, January 10th. Morgan Stanley lowered their target price on shares of GoodRx from $7.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Tuesday, December 17th. Finally, Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $5.00 target price for the company. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.18.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.